KIT and gastrointestinal stromal tumor: Figure 1b shows that TAS-116 inhibited the proliferation of IM-naïve and IM-resistant GIST cell lines similarly in a dose-dependent manner, whereas it inhibited the proliferation of GIST R2 cells to a lesser extent, in which the growth is not dependent on KIT activation under imatinib existence (Fig. 1c).